NAMS
NASDAQNewAmsterdam Pharma Company N.V.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks44-50%
2025-12-072026-05-31
Mix1590d
- SEC Filings8(53%)
- Insider4(27%)
- Other2(13%)
- Analyst1(7%)
Latest news
25 items- SECNewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- INSIDERChief Accounting Officer Kooij Louise Frederika exercised 65,000 units of Ordinary Shares at a strike of $10.07 and sold $2,319,850 worth of Ordinary Shares (65,000 units at $35.69) as part of a pre-agreed trading plan (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by NewAmsterdam Pharma Company N.V.SCHEDULE 13D/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- SECNewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECSEC Form 10-Q filed by NewAmsterdam Pharma Company N.V.10-Q - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.SCHEDULE 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- SECSEC Form DEF 14A filed by NewAmsterdam Pharma Company N.V.DEF 14A - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECNewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Leadership Update8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECSEC Form PRE 14A filed by NewAmsterdam Pharma Company N.V.PRE 14A - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- ANALYSTTruist initiated coverage on NewAmsterdam Pharma with a new price targetTruist initiated coverage of NewAmsterdam Pharma with a rating of Buy and set a new price target of $57.00
- INSIDERDirector Lange Louis G sold $1,357,230 worth of Ordinary Shares (44,619 units at $30.42), decreasing direct ownership by 81% to 10,360 units (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- SECSEC Form 144 filed by NewAmsterdam Pharma Company N.V.144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- INSIDERDirector Lange Louis G sold $828,950 worth of Ordinary Shares (28,186 units at $29.41) and exercised 44,619 in-the-money units of Ordinary Shares at a strike of $11.50, increasing direct ownership by 431% to 54,979 units (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- INSIDERChief Scientific Officer Kastelein Johannes Jacob Pieter converted options into 300,000 units of Ordinary Shares and sold $9,090,868 worth of Ordinary Shares (300,000 units at $30.30) (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- SECSEC Form 144 filed by NewAmsterdam Pharma Company N.V.144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- INSIDERChief Executive Officer Davidson Michael H. converted options into 443,707 units of Ordinary Shares and sold $14,753,258 worth of Ordinary Shares (443,707 units at $33.25) (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- SECSEC Form 144 filed by NewAmsterdam Pharma Company N.V.144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- SECNewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- INSIDERChief Scientific Officer Kastelein Johannes Jacob Pieter sold $1,605,998 worth of Ordinary Shares (45,481 units at $35.31), decreasing direct ownership by 46% to 53,500 units (SEC Form 4)4 - NewAmsterdam Pharma Co N.V. (0001936258) (Issuer)
- SECSEC Form 144 filed by NewAmsterdam Pharma Company N.V.144 - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- SECSEC Form S-8 filed by NewAmsterdam Pharma Company N.V.S-8 - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECSEC Form 10-K filed by NewAmsterdam Pharma Company N.V.10-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECNewAmsterdam Pharma Company N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NewAmsterdam Pharma Co N.V. (0001936258) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by NewAmsterdam Pharma Company N.V.SCHEDULE 13G/A - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
- SECSEC Form SCHEDULE 13G filed by NewAmsterdam Pharma Company N.V.SCHEDULE 13G - NewAmsterdam Pharma Co N.V. (0001936258) (Subject)
NAMS FAQ
5 questionsWhere does NAMS stock trade?
NewAmsterdam Pharma Company N.V. (NAMS) is listed on NASDAQ.What sector and industry is NAMS in?
NewAmsterdam Pharma Company N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about NAMS?
NewAmsterdam Pharma Company N.V. has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-03-18. Recent price targets range from $2700.00 to $4800.00.What companies are similar to NAMS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NAMS side-by-side with any of them on Quantisnow.How can I track NAMS on Quantisnow?
Quantisnow aggregates NewAmsterdam Pharma Company N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NAMS to receive live email and push alerts on every new disclosure.